Eaton Vance Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Eaton Vance Management’s Portfolio BHVN Stock Details BHVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$5.43M	Buy	35,908 +1,199	+3%	+$178K	0.01%	753
2022 Q2	$5.06M	Buy	34,709 +4,589	+15%	+$586K	0.01%	805
2022 Q1	$3.57M	Buy	30,120 +29,949	+17,514%	+$3.74M	﹤0.01%	988
2021 Q4	$24K	Sell	171 -135	-44%	-$17.2K	﹤0.01%	2358
2021 Q3	$3K	Buy	306 +185	+153%	+$23.1K	﹤0.01%	1910
2021 Q2	$12K	Buy	+121	New	+$9.82K	﹤0.01%	2524

Other funds holding BHVN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Eaton Vance Management's BHVN Position: Q3 2022 in Review

Eaton Vance Management increased its Biohaven Pharmaceutical Holding Company Ltd. (BHVN) stake by 3.5% in Q3 2022, buying an estimated $178K and bringing the position to 35,908 shares worth $5.43M. The position accounts for 0.01% of the portfolio, ranked #753.

Eaton Vance Management first reported a position in BHVN in Q2 2021 and has held it in 6 quarters since. 240 funds tracked by Wall St. Rank hold BHVN as of Q3 2022.

Eaton Vance Management held 35,908 shares of Biohaven Pharmaceutical Holding Company Ltd. worth $5.43M as of Q3 2022.
Eaton Vance Management bought 1,199 Biohaven Pharmaceutical Holding Company Ltd. shares in Q3 2022, an estimated $178K.
Biohaven Pharmaceutical Holding Company Ltd. made up 0.01% of Eaton Vance Management's portfolio in Q3 2022, its #753 holding.
Eaton Vance Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2021 and has held it in 6 quarters since.
240 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.